Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$25.26
-0.9%
$23.68
$13.40
$26.65
$4.26B0.751.92 million shs1.11 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$53.01
+6.6%
$37.62
$29.31
$59.39
$5.95B0.622.54 million shs3.72 million shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$150.27
+0.3%
$146.65
$122.80
$207.84
$4.35B0.66254,453 shs324,265 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$15.05
+6.9%
$13.63
$9.03
$17.70
$1.13B1.27528,693 shs627,107 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-0.94%-2.81%+6.13%+14.92%+51.35%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+6.55%+50.04%+50.85%+64.12%-3.43%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+0.35%+1.74%+10.49%+9.73%-19.19%
Zymeworks Inc. stock logo
ZYME
Zymeworks
+6.89%+1.62%+21.27%+19.44%+29.85%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$25.26
-0.9%
$23.68
$13.40
$26.65
$4.26B0.751.92 million shs1.11 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$53.01
+6.6%
$37.62
$29.31
$59.39
$5.95B0.622.54 million shs3.72 million shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$150.27
+0.3%
$146.65
$122.80
$207.84
$4.35B0.66254,453 shs324,265 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$15.05
+6.9%
$13.63
$9.03
$17.70
$1.13B1.27528,693 shs627,107 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-0.94%-2.81%+6.13%+14.92%+51.35%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+6.55%+50.04%+50.85%+64.12%-3.43%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+0.35%+1.74%+10.49%+9.73%-19.19%
Zymeworks Inc. stock logo
ZYME
Zymeworks
+6.89%+1.62%+21.27%+19.44%+29.85%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.61
Moderate Buy$28.8814.31% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.87
Moderate Buy$75.3842.21% Upside
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2.88
Moderate Buy$210.3840.00% Upside
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.90
Moderate Buy$21.4342.38% Upside

Current Analyst Ratings Breakdown

Latest ZYME, ACAD, KRYS, and CYTK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$53.00 ➝ $71.00
9/3/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$60.00 ➝ $80.00
9/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$77.00 ➝ $84.00
9/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$87.00 ➝ $96.00
9/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$78.00
9/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$72.00
8/22/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$219.00 ➝ $216.00
8/22/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$240.00
8/11/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$19.00 ➝ $22.00
8/8/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$32.00 ➝ $36.00
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.02B4.18$0.70 per share36.18$4.40 per share5.74
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$18.47M343.43N/AN/A($1.15) per share-46.10
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$359.21M12.11$4.65 per share32.29$32.90 per share4.57
Zymeworks Inc. stock logo
ZYME
Zymeworks
$122.87M9.21N/AN/A$6.63 per share2.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$226.45M$1.3318.9933.246.4621.80%14.69%9.41%11/5/2025 (Estimated)
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$589.53M-$5.10N/AN/AN/A-707.17%N/A-45.52%11/5/2025 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$89.16M$4.9230.5414.91N/A40.85%15.21%13.81%11/3/2025 (Estimated)
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)

Latest ZYME, ACAD, KRYS, and CYTK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.34-$1.12+$0.22-$1.12$1.95 million$66.77 million
8/7/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.52$0.03+$0.55N/A$17.18 million$48.73 million
8/6/2025Q2 2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.14$0.16+$0.02$0.16$263.07 million$264.57 million
8/4/2025Q2 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.08$1.29+$0.21$1.29$95.42 million$96.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
2.91
2.83
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
6.76
6.76
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
9.68
9.33
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.50%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.70%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.70%
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510168.71 million124.00 millionOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250119.66 million116.43 millionOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21028.94 million24.98 millionOptionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
46075.17 million67.56 millionOptionable

Recent News About These Companies

Bloom Burton Comments on Zymeworks FY2025 Earnings
Zymeworks (NYSE:ZYME) Shares Gap Down - What's Next?
Zymeworks Inc. $ZYME Stake Reduced by Redmile Group LLC
Zymeworks Inc. $ZYME Shares Acquired by Vestal Point Capital LP
Health Sector Innovations: From Blood Thinners to Bird Flu Outbreaks
Zymeworks Reports Q2 Results and FDA Clearance

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$25.26 -0.24 (-0.94%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$25.15 -0.11 (-0.44%)
As of 09/5/2025 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$53.01 +3.26 (+6.55%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$52.51 -0.50 (-0.94%)
As of 09/5/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$150.27 +0.52 (+0.35%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$150.54 +0.26 (+0.18%)
As of 09/5/2025 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Zymeworks stock logo

Zymeworks NYSE:ZYME

$15.05 +0.97 (+6.89%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$15.18 +0.13 (+0.83%)
As of 09/5/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.